Eucrisa is Not a steroid. On March 25, 2020, the FDA approved Pfizer’s supplemental new drug application for Eucrisa ointment, 2%, for children as young as age 3 months with mild-to-moderate atopic dermatitis. In the study, Eucrisa was well tolerated and demonstrated effectiveness in patients with eczema with no new safety signals identified. In December 2016, the FDA approved Eucrisa for the treatment of mild to moderate atopic dermatitis in adults and children older than two years of age. Eucrisa reduces inflammation, redness and itching in eczema. The potency of Eucrisa is probably similar to a low potency cortisone cream. Unlike steroids, Eucrisa does not produce thinning of the skin, stretch marks or bruising. The main side effects are burning and stinging, particularly with the first and second applications. Often, Eucrisa is used in combination with topical steroids to help maintain control of eczema. Eucrisa may be used continuously on normal appearing skin.